Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 16/20 | 1.00 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372684 | 0.90 | SIGMAR1 (0.82) | SIGMAR1TMEM97ACKR3OPRM1 | |
| SCHEMBL17372472 | 0.89 | SIGMAR1 (1.00) | SIGMAR1TMEM97ACKR3OPRM1 | |
| SCHEMBL13947507 | 0.87 | SIGMAR1 (0.79) | SIGMAR1TMEM97ACKR3OPRM1 | |
| SCHEMBL17372403 | 0.86 | SIGMAR1 (1.00) | SIGMAR1TMEM97ACKR3OPRM1 | |
| SCHEMBL17372401 | 0.86 | SIGMAR1 (1.00) | SIGMAR1TMEM97ACKR3OPRM1 | |
| SCHEMBL17372504 | 0.86 | SIGMAR1 (1.00) | SIGMAR1TMEM97ACKR3OPRM1NPC1 | |
| SCHEMBL13579952 | 0.85 | SIGMAR1 (0.83) | SIGMAR1TMEM97ACKR3OPRM1 | |
| SCHEMBL17372597 | 0.84 | SIGMAR1 (1.00) | SIGMAR1TMEM97ACKR3OPRM1 | |
| SCHEMBL17372475 | 0.84 | SIGMAR1 (1.00) | SIGMAR1TMEM97ACKR3OPRM1 | |
| SCHEMBL17372581 | 0.83 | SIGMAR1 (1.00) | SIGMAR1TMEM97ACKR3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154934-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE (FR) | 2021-04-14 | — | — | EP | claimed |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE II DROIT & SANTE (FR) | 2021-02-11 | — | — | US | claimed |
| CN-106795100-B | Compound, pharmaceutical composition and its purposes in treatment neurodegenerative disease | 里尔大学 | 2019-11-19 | — | — | CN | claimed |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-03-28 | — | — | US | claimed |
| EP-3154934-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE (FR) | 2021-04-14 | — | — | EP | disclosed |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE II DROIT & SANTE (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2020-11-24 | — | — | US | disclosed |
| CN-106795100-B | Compound, pharmaceutical composition and its purposes in treatment neurodegenerative disease | 里尔大学 | 2019-11-19 | — | — | CN | disclosed |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-03-28 | — | — | US | disclosed |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-01-15 | — | — | US | disclosed |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | disclosed |
| EP-3154934-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015193255-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885TMEM97 2094/4885ACKR3 4070/4885 |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885TMEM97 2094/4885ACKR3 4070/4885 |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885TMEM97 2094/4885ACKR3 4070/4885 |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885TMEM97 2094/4885ACKR3 4070/4885 |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | SIGMAR1 1439/4885TMEM97 2094/4885ACKR3 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.